Net Income

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

The LA Rams and energy firm CRC mark one year of a partnership to offset team emissions, but does this innovative, local-first model truly change the game?

With pivotal data for its sickle cell drug and a new myelofibrosis program, Cellarity's AI-driven 'Cell State-Correcting' platform faces a crucial test.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

A new survey shows no firm recovers from cyberattacks in a day, with downtime lasting weeks. Yet, executive focus on resilience may be dangerously waning.

After 30 years, CEO Jim Foster will retire, passing the torch to COO Birgit Girshick in a move that signals continuity and a new era of governance.

Klotho Neurosciences will present its novel gene therapy for Alzheimer's and ALS at a key summit, seeking to turn scientific promise into clinical reality.

A new partnership aims to bring cutting-edge cancer trials to community clinics, accelerating drug development and expanding patient access to care.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

Quantum PKI appoints Dr. Judy Gounden as CEO, signaling a strategic push for global growth, crypto-agility, and diverse leadership in digital trust.

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

With gold hitting record highs, investors are keenly awaiting Kinross's update on three critical US projects that could define its production for a decade.

Cybersecurity firm Corero appoints an award-winning leader to supercharge its partner program, signaling a major push in the competitive DDoS defense market.

Calgary-based Horizon Petroleum faces a Management Cease Trade Order over delayed financial filings, raising questions about its European operations.

Challenger brand Kodiak partners with analytics giant NIQ, signaling a new data-driven era for competition in the crowded CPG breakfast and snacking aisles.

Luxury brand owner Tapestry partners with Pivot Energy on Illinois solar projects, powering homes and funding new green job training programs for locals.

Westwater Resources heads to a key investor conference, carrying the weight of its Alabama graphite projects and the future of America's EV supply chain.

Amid market headwinds, JD.com cancels $3B in shares to boost value, signaling deep confidence while juggling costly strategic growth initiatives.

A major customer delay impacts Ceragon's Q4 revenue, but the company projects significant growth in 2026, banking on a strong backlog and new markets.